DNAPrint Files Patent for Another Component of its Informatics Platform
SARASOTA, Fla.--(BW HealthWire)--Jan. 8, 2002--DNAPrint genomics, Inc. (OTCBB:DNAP) announced today that it has filed a US patent application to protect another key component of its developing informatics platform. The patent, entitled "A CORRESPONDENCE METHOD FOR CONSTRUCTING COMPLEX GENETICS CLASSIFIERS" was filed recently with the United States Patent and Trademark Office.
In scientific terms, the patent covers proprietary methods for creating statistical models from population genetic data. The method is a powerful multivariate graphical procedure to study the association between variables (i.e. instances of genetic features) and attributes (i.e. trait values). It can be considered a scaling method linked to principal component analysis and cononical correlation analysis, with unique modifications for population genetics data.
In lay terms, the algorithm is used to assemble the "puzzle pieces" of a complex genetic "picture". The puzzle pieces, or "genetic features" are discovered using the company's "Haploscope" algorithm, which is also patent pending. Genetic features can be used to distinguish between different classes of patients (such as responders and non-responders). Just as features (such as nose shape, hair color, weight, voice and height) visually identify people in everyday life, features are also useful for distinguishing between groups of patients. Once the features have been identified, they can be combined into classifiers, which can be used, en masse, to predict patient drug response in a commercial setting. The invention covered by this patent application describes a novel method for assembling identified genetic features into a classifier, and thus represents an important step in the development of personalized drug prescription products.
Because most drug reaction traits are functions of multiple interacting genes, DNAPrint believes that only properly identified and modeled genetic features will allow the development of Pharmacogenomics classifiers with the sensitivity and specificity necessary for use in personalized drug prescription. The company is developing an informatics platform to effect this analytical process. The invention covered by the patent application announced today comprises merely one component of this platform, and because of its central role in the ongoing discovery efforts at DNAPrint, it constitutes a significant part of DNAPrint's competitive position.
About DNAPrint genomics, Inc.:
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and statistical modeling, programming and molecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit dnaprint.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
CONTACT: DNAPrint genomics, Inc., Sarasota
For Scientific inquiries:
Tony Frudakis, Ph.D., 941/366-3400
or
Other inquiries
Tim Wilkins, 941/923-1949 |
